Kestrel Labs, Inc. Receives The Cavendish Impact Foundation Innovator Award

Forum uniquely brings together leading family offices, foundations, and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences

Kestrel Labs, Inc., a medical device company working on laser-based medical monitoring techniques that hold the promise of a new generation of monitoring devices, announced today that it presented at the Cavendish Global Health Impact Forum held July 18-20, 2017 at the University Club of Chicago in Chicago, IL, co-hosted with the Illinois Biotechnology Industry Organization (iBIO), PROPEL at the iBIO Institute, and the Innovation and New Ventures Office (INVO) at Northwestern University. Kestrel Labs was also one of two organizations to receive the inaugural Cavendish Impact Foundation Innovator Award.

The Forum provided an environment for family offices, foundations, and impact investors to develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcased presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies, and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish Health Impact Forums are hosted by leading institutions around the world and take place four times each year.

Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Kestrel Labs’ research and development in the use of low-cost lasers in pulse oximetry positions them to make a major contribution to the field of noninvasive medical monitoring.”


“It was an honor to be selected to present at this unique event, as it is further confirmation that our innovative and groundbreaking improvements in the field of pulse oximetry will have a real impact on the lives of many patients by eliminating some of the most severe deficiencies that oximeters have had in their performance and accuracy that have not been addressed in the 35+ years since these monitors were first commercially launched,” said Jonas Pologe, Kestrel Labs CEO and co-founder. “We welcomed the chance to interact with this dynamic group of accomplished scientists, thought-leaders, and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world, and we are further honored to have our presentation recognized with the Cavendish Impact Foundation Innovator Award."


Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.


Full information is available on the Kestrel Labs website.

Go Back